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The observation that T helper cells recognize antigen in the context of an
MHC class II product has generated enormous interest in the structure and
function of these cell surface glycoproteins . Studies demonstrating that, in many
cases at least, the antigen recognized is in the form of a short peptidic fragment
(1) and that such peptides bind directly to a single site on solubilized class II
molecules (2), have clarified our understanding of the interactions between the
T cell receptor (TCR), antigen, and class II product . These binding studies have
suggested that some of the immune response (Ir) gene effects observed in mice
of different H-2 type might reflect differences in the ability of their class II
molecules to bind the relevant antigenic peptide (3) . A more precise analysis of
the molecular interactions between the class II product, antigen andTCR would
be of obvious value in understanding the basis for MHC disease associations and
in vaccine design .
Much work in murine experimental models has been devoted to the introduc-
tion by DNA-mediated gene transfer of individual MHC class II products into
nonexpressing cells, so that the requirements for presentation of antigen by
these molecules can be studied in a defined, manipulable system (4) . Such stud-
ies have shown that transfected H-2 gene products can be expressed on the sur-
face ofmouse L cells and that this expression is sufficient to confer the property
of antigen presentation upon the L cell, with respect to synthetic peptides, and
in some cases, whole protein antigens (5, 6) . Furthermore, analysis of the molec-
ular basis of the interactions involved in presentation using exon-shuffled, trans-
fected la molecules has led to the suggestion that separate sites may be respon-
sible for peptide binding and for interaction with the TCR (7) .
The HLA class II region encodes at least three expressed products ; DP, DQ,
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and DR (8), each of these being highly polymorphic and capable of acting as
restriction elements for T cell recognition (9). Given the association of many
diseases with particular HLA types, and the view that products of the different
subregions may perform differential roles in the immune response (10), the
development of an in vitro system where the function of defined gene products
can be examined in isolation is a desirable objective. While the cloning and
sequencing of human, HLA class II genes has generated a large amount of
information about the organization and polymorphism of the HLA class II
genetic region, experiments reporting the use of DNA-mediated gene transfer
to investigate the function of the encoded products have been limited (11, 12).
We have used transfection to analyze biochemical and functional aspects of
the DRS genes of the HLA-DR2Dw2 haplotype, an HLA type of considerable
interest owing to its association with a number of diseases such as narcolepsy
(13), Goodpasture's syndrome (14), tuberculoid leprosy (15), and multiple scle-
rosis (16). There are two expressed DRS genes in DR2 haplotypes and on the
basis of cDNA sequencing and biochemical studies, one appears to vary mark-
edly between the cellularly defined subtypes of DR2 (Dw2 and Dw12) while the
other is more conserved (17-19). These genes have been termed DR20 a (or
St) and DR2S b (or S2), respectively. The concomitant expression of these two
genes, together with the lack of a clear serological distinction between their
encoded products, has prohibited a clear understanding of their relative contri-
bution to HLA serology, biochemistry, and function. Using cDNA clones, we
have produced L cell transfectants separately expressing high levels of these two
HLA-DR products in order to address these questions.
We report here the separate expression of cDNA clones representing the two
DR2S genes in mouse L cells, allowing unequivocal assignment of the biochem-
ically defined protein products to the individual cDNA sequences. Furthermore,
such L cell transfectants expressing high levels of HLA class II products can
efficiently present either peptidic or whole antigens to human T cells and have
enabled us to define the restriction element used by T cell clones from DR2
patients with leprosy. This is a disease where, due to the association of different
clinical symptoms with HLA-type (20), there has been considerable interest in
defining the mycobacterial and HLA epitopes involved (21) .
Materials and Methods
Isolation of cDNA Clones and Expression Vector Constructions.
￿
Double-stranded cDNA
was prepared from 5 ug of poly(A)+ mRNA (22) extracted from the B-lymphoblastoid
cell line (B-LCL)' ROF (DR2Dw2, DR4Dw4). The cDNA was ligated using Eco RI linkers
to Eco Rl-digested bacteriophage Xgt10 arms (Vector Cloning Systems, San Diego CA)
and a library of 400,000 recombinants propagated on Escherichia coli NM514 cells. The
cDNA library was screened by filter hybridization (23) using a radioactively labeled oli-
gonucleotide probe specific for the 5' end of DRS genes. DR3 cDNA clones were
sequenced in both directions by the chain termination method (24) and two full-length
clones corresponding to the two expressed DRS genes from the DR2 haplotype were
identified.
1 Abbreviations used in this paper.
￿
B-LCL, B-lymphoblastoid cell line; HMT, hypoxanthine, meth-
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DR/3 clones corresponding to the two expressed DR2 ,B chains (designated DR2,6 a
and DR2# b) and a full-length DRa cDNA clone (donated by H. Ikeda, Imperial Cancer
Research Fund, London) were ligated into the Eco RI site of the Moloney Leukemia
virus-based cDNA expression vector pJ4 (Fig. 1) and subclones were restriction mapped
for the orientation of the cDNA clones in the expression vector.
Transfection of DR2,8a and DR2,8b cDNA Clones into Mouse L Cells.
￿
The DR20 a/pJ4
and DR2# b/pJ4 constructs were separately cotransfected together with the DRa pJ4
construct and the plasmid pOPF (25) containing the HSV thymidine kinase gene, into
mouse Ltk- cells using the calcium phosphate technique (26) . Transfectants were grown
in DME (Flow Laboratories, Rickmansworth, United Kingdom) supplemented with 10%
FCS (Gibco Laboratories, Paisley, Scotland) and selected using HMT (10-4 M hypoxan-
thine, 10-5 M methotrexate, and 1.6 X 10-5 M thymidine) . HMT-resistant colonies
resulting from each transfection were pooled, stained with the pan-class 11 mAb SG465
(27), analyzed by flow microfluorimetry, and repeatedly sorted to obtain transfectants
expressing high levels of cell surface expression of DRa/DR2,6 a and DRa/DR2/3 b
heterodimers.
Flow Microfluorimetric Analysis.
￿
106 cells were washed with cold PBS containing 5%
FCS and incubated with 100 ul of antibody (diluted in PBS + 5% FCS) for 30 min on
ice. mAbs were used either as neat supernatant, ascites diluted 1:100 or purified Ig at a
concentration of 50 tg/ml. After two more washes in PBS + 5% FCS, the cells were
resuspended in 50 jl of a 1:10 dilution of FITC-conjugated rabbit anti-mouse IgG (Cap-
pel Laboratories, Malvern, PA) and incubated for a further 30 min on ice. After two
final washes, the cells were analyzed on the FACS (constructed at The Imperial Cancer
Research Fund) with log amplifier.
Northern Blot Analysis.
￿
20-jug samples of total RNA were loaded onto a 1% agarose
gel containing 2.2 M formaldehyde (28) and electrophoresed for 20 h at 20 mA. Gels
were blotted onto Hybond N (Amersham, Slough, United Kindgom) and probed with
full-length DRa or DR,Q cDNA probes. The labeled blots were then exposed overnight at
-70° to Kodak XAR5 film.
Monoclonal Antibodies.
￿
The specificities of the mAbs used in the FACS analyses, T cell
inhibition assays, and immunoprecipitations are as follows: SG465 (27), TDR31.1 (29),
and CA2 (30): broadly reactive anti-HLA class II-specific mAbs. DA6.164 (31): anti-
HLA-DR (except DR7). HU-30 (32): anti-HLA-DR2 and DR1. TAL1B5 (33): anti-DRa.
B7.21 (34) : anti-HLA-DP. Leu-10 (Becton Dickinson & Co., Mountain View, CA): anti-
HLA-DQ. Genox 3/53 (35): anti-HLA-DQwl . W6/32 (36): anti-HLA class 1. Leu-3a
(Becton Dickinson & Co.): anti-CD4. MHM.23 (37): anti-LFA-1 # chain (CD18) .
MHM.24 (37): anti-LFA-1 a chain (CDlla)
Two-Dimensional Gel Electrophoresis.
￿
Briefly, 5 X 106/ml cells were incubated for 4 h
in methionine-free medium supplemented with 10% FCS and 1 MCi/ml [s5S]methionine
(Amersham) and then lysed in 5 mM Tris, pH 7.4/0.1 M NaCl/4 mM EDTA/0.5% NP-
40 . After 30 min on ice, the lysates were cleared of solid material by centrifugation,
precleared twice with fixed Staphylococcus aureus (The Enzyme Center, Boston, MA), and
incubated at 4°C with mAb TALIB5 (33) before precipitation with rabbit anti-mouse
Ig/S. aureus. Immunoprecipitates were dissolved in IEF sample buffer (9 M urea, 4%
NP40, 2% 2-ME, 2% ampholine (pH 6-8, 80%; pH 3.5-10, 20%) at 50°C, centrifuged,
and the supernatants were loaded onto the gel (38). The first dimension IEF was per-
formed in tube gels in 4% polyacrylamide, 9.2 M urea, 2% wt/vol NP-40 and 2% ampho-
lines. After focusing for 17 h at 800 V, tube gels were extruded and loaded for second
dimension SDS-PAGE on 11 % gels. Finally, gels were fixed, immersed in Amplify (Amer-
sham), vacuum dried, and exposed to Kodak XAR-5 film.
Cells.
￿
The B-lymphoblastoid cell lines ROF-LCL (cDNA clone donor), REIZ-LCL (T
lymphocyte clone donor [DR2Dw2, DR3]), and TOKUNAGA (TOK.LCL; homozygous
DR2Dwl2) were propagated in RPMI 1640 (Gibco Laboratories) + 10% FCS. The T
lymphocyte clones 2F9 and 2F10 specific for Mycobacterium leprae antigen and restricted
by DR2 have been extensively described elsewhere (39). Clone 2D6, also specific for M.
leprae and restricted by DR2, was derived from a DR2Dw2,DR4Dw13 individual. The TWILKINSON ET AL .
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cells were propagated in Iscove's Modified Dulbecco's Medium (Gibco Laboratories),
supplemented with 10% human serum and 10% Lymfocult T as a source of IL-2 (Biotest,
Frankfurt, Federal Republic of Germany) .
Proliferation Assays.
￿
For use in proliferation assays, transfectants grown to confluence
were washed in RPMI 1640, resuspended at 5-10 X 106 in cells/ml in mitomycin C
(Sigma Chemicals, Poole, United Kingdom) at a final concentration of 100 jug/ml, and
incubated at 37°C for 1 h before washing several times . B-lymphoblastoid cell lines were
irradiated with 80 Gy. 10 4 cloned T lymphocytes and 5 X 10' transfectants or B-lym-
phoblastoid cell lines were added to 96-well, flat-bottomed microtiter plates (Greiner,
Nurtingen, FRG) . Peptide (p17, a 24-residue Mleprae 65-kD antigen peptide added at
0.01 ug/ml unless otherwise indicated), recombinant 65-kD M. leprae antigen (Y4178
added at 10Ag/ml [40]), or M. leprae antigen (soluble M . leprae antigen purified
from armadillo according to Immunology of Leprosy (IMLEP) protocol 1-79 and
obtained from IMLEPM. leprae Bank by courtesy of Dr. R . Rees ; added at 1-20 ug/ml
as indicated), were added as a source of antigen . PHA was used at a concentration of 4
jug/ml (Wellcome Diagnostics, Beckenham, United Kingdom) . Some assays contained
mAbs added as dialyzed and filtered ascites . Assays were set up in triplicate, cultured for
72 h with the addition of I uCi/well ['Hlthymidine (Amersham) for the final 6 h, and
harvested on filter discs using an automated cell harvester, before adding scintillant and
counting in a scintillation counter (G. D . Searle and Co ., Chicago, IL) .
Results
Isolation ofHLA-DR2,B a and DR2,B b cDNA Clones and Transfection into Mouse
L Cells. Two full-length cDNA clones were isolated that correspond exactly in
sequence to the published DR2# a (or ,B I) and DR2,Q b (or 02) sequences for the
DR2Dw2 homozygous cell line PGF (18, 19) . These cDNA sequences will be
referred to as DR20 a and DR2# throughout (Fig . 1 a) . The DR2,Q a and DR2p
FIGURE 1 . ,B1 domain amino acid
sequences of the cDNA clones
DR2# a and DR20 b from the DR2
haplotype and subdoning of these
sequences into the expression vector
pJ4. (a) The sequences of the cDNA
clones isolated are identical to the
published sequences for the DR2f a
and DR20 b cDNA clones from
the DR2Dw2 haplotype (18, 19) .
The equivalent sequences of the
DR2Dw12 haplotype are shown for
comparison . Sequences are shown
using the one-letter amino acid
code . (b) Both cDNA clones and a
cDNA clone for DRa (sequence not
shown) were subcloned into the
cDNA expression vector pJ4, which
contains the Moloney murine leuke-
mia virus long terminal repeat (Mo-
MULV LTR) as promoter, the SV40
small t intervening sequence (SV40 t
IVS), and SV40 large T polyadenyl-
ation site (SV40 T poly A site) .b cDNA clones were subcloned into the Moloney leukemia virus-based expres-
sion vector pJ4 (a vector shown to give high levels of transcription in L cells,
our unpublished observations) and then separately transfected into mouse L
cells together with a DRa/pJ4 construct (Fig. 1 b). The resultant transfectant
cell lines, LDR2a and LDR2b, were subjected to four rounds of flow fluorime-
tric sorting to obtain cells expressing high levels of surface expression (>50%
of an EBV-transformed B-LCL, as measured by flow microfluorimetry) of the
transfected gene products. Southern analysis confirmed the presence of both
DRa and 0 gene sequences in genomic DNA from the transfectants and North-
ern analysis demonstrated the presence of high levels of RNA transcripts from
both genes (data not shown).
Flow Microfluorimetric Analysis of L Cell Trawsfectants Expressing Products of the
HLA-DR2,Ba and HLA-DR2,Bb Genes. Analysis of the LDR2a and LDR2b trans-
fectants using flow microfluorimetry and a panel of anti-HIA class II-specific
mAbs clearly shows them to be expressing HLA class II products (Fig.2), as evi-
denced by their binding of the pan-HLA class II mAbs SG465 and CA2 and
more specifically, HLA-DR products, as indicated by their binding of the HLA-
DR-specific mAb DA6.164 and lack of reactivity with 137/21 (anti-HLA-DP) and
Leu-10 (anti-HLA-DQ) . Of all the mAbs tested, TDR31 .1 was the only mAb to
discriminate between the transfectants, having a higher affinity for the DRa/
DR20 a heterodimer. Interestingly, this mAb has been shown to recognize deter-
W
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FIGURE 2. Flow microfluorimetric analysis of
the transfectant cell lines LDR2a and LDR2b
(which express cell surface DRa/DR2 a and
DRa/DR2/3 6 heterodimers, respectively) using a
panel of anti-HLA class II mAbs. The reported
specificities of the mAbs shown are: SG465 (anti-
HLA-DP/DQfDR), TDR31.1 (anti-HLA-DP/DR),
DA6.164 (anti-HLA-DR, except DR7), HU-30
(anti-HLA-DR2 and DRl), 137/21 (anti-HLA-DP),
and Leu-10 (anti-HLA-DQ). 104 cells were ana-
lyzed in each profile andresults are plotted as log
fluorescence intensity (abscissa) against cell num-
ber (ordinate). In each profile, the negative con-
trol is the transfectant cell line stained with
FITC-rabbit anti-mouse Ig alone.WILKINSON ET AL .
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FIGURE 3 .
￿
Two-dimensional gel analysis of the immunoprecipitated products from the bio-
synthetically labeled cell lines PGF (homozygous DR2Dw2 B-cell line), LDR2a, and LDR2b,
using the anti-HLA-DRa mAb TALIB5 . Isoelectric focusing was performed as the first
dimension and SDS-PAGE as the second. The coprecipitated a and ,B spots are labeled . The
set of spots corresponding to the ,B chain that is electrophoretically variable among DR2
subtypes is designated ,B a, and those corresponding to the electrophoretically constant 0
chain are designated ,B b .
minants on the #1 domain (Jill Maddox, personal communication) . The fact that
HU-30 bound to both transfectants is surprising in the light of previous immu-
noprecipitation and two-dimensional (2D)-PAGE studies which suggested that
this mAb is specific for the DRa/DR2# b heterodimer (41, 42) .
2D-PAGE Analysis of the DR2,& a and DR2,& b Chains.
￿
2D-PAGE analysis of
biosynthetically labeled extracts from the DR2Dw2 homozygous B-LCL PGF
after immunoprecitation with the DRa specific mAb TAL I B5, reveals the pres-
ence of two coprecipitated ,8 chains (Fig. 3) . The electrophoretic mobilities of
these two expressed DR2 a chains are related to the DR2 subtype : the more
acidic a (or #I) chain has a variable position of migration dependent upon the
Dw type of the cell line, whereas the b (or 02) chain has an invariant position of
migration irrespective of the Dw type (18, 19, 42) . When TALIB5 immunopre-
cipitates from the LDR2a and LDR2b transfectants were examined, the DRa
chain and a set of spots corresponding to the different glycosylated forms of the
0 chain were clearly visible . Comparison of the localization of the DRa chains
in PGF and in the transfectants unequivocally shows that of the two 0 chains
present in PGF, the more acidic, variable 0 chain is the only 0 chain present in
the LDR2a transfectant, the more basic, constant (3 chain the only one present
in the LDR2b transfectant . The variable ,8 chain can thus formally be defined
as the product of the DR2# a cDNA sequence and the more constant ,Q chain
as that of the DR2f b sequence, as has been proposed on the basis of biochem-
ical and sequencing studies (18, 19) .1448
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FIGURE 4 . DR2 transfected
L cells present M.leprae pep-
tide to T cells . L cell transfec-
tants and the autologous B-
LCL (REIZ) were tested as
APC for the T cell clone
2F10 . Bars represent the
standard errors from the
mean of triplicate cultures .
DR2-Transfected L Cells Present Peptide to T Lymphocyte Clone 2FI0 .
￿
T lympho-
cyte clone 2F10, derived from a tuberculoid leprosy patient is specific for the
M.leprae 65-kD antigen and has been shown from mapping with B-LCL and anti-
body blocking to be DR2 restricted (39) . The clone recognizes a peptide, p17,
synthesized from the 65-kD antigen sequence and initially localized by screening
2F10 on deletion mutants of the 65-kD antigen expressed in E.coli (Thole, G .,
et al ., submitted for publication) . Five other peptides from the 65-kD sequence
shown to be stimulatory for T lymphocyte clones (TLCs) restricted by other DR
alleles were not recognized by 2F10 . TLC 2F10 responds equally well to antigen
whether presented by the autologous B-LCL, REIZ(DR2Dw2, DR3), by the
cDNA donor B-LCL ROF(DR2Dw2, DR4) (data not shown) or by the DR2Dw12
homozygous B-LCL TOK (39) . Since the Dw2 and Dw12 subtypes of DR2 are
largely similar with respect to the DR2, b sequence but also show important
regions of sequence homology in the DR2 ,Q a gene (18, 19), these B-LCL pre-
sentation studies could not define the DR20 chain used by 2F10 . We were there-
fore interested to see whether either of the L cell transfectants could present
antigen to this clone .
When the two DR2 transfectants were tested for the ability to present p17 to
clone 2F10, LDR2a was shown to present efficiently (Fig. 4) . The LDR2b trans-
fectant, in spite of expressing a similar level of surface DR, had no stimulatory
effect on the T cells, generating a response as low as the mock transfectant . This
inability to present was not overcome by increasing the peptide concentration
10-fold to 0.1 ttg/ml . Thus, DR2-transfected mouse L cells can present peptide
to human T cells and clone 2F10 is restricted by the DRa/DR3 a heterodimer .
Antigen presentation by the LDR2a transfectant and the autologous B-LCL
were then compared with respect to susceptibility to mAb blocking (Fig . 5) . Pre-
sentation to 2F10 by the B-LCL was largely abrogated by the class 11 framework
mAb, CA2, with the anti-CD4 mAb Leu-3a able to suppress the response by
^-60% . Antibodies against the LFA-la (CDlla) and LFA-1,Q (CD18) chains
blocked the response almost as well, the anti-HLA-DQ antibody Genox 3/53a
WILKINSON ET AL.
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￿
Antibody blocking of presentation to clone 2F10. The autologous B-LCL (REIZ)
(a) or the LDR2a transfectant (b), were tested for presentation of p17 (added to cultures at
0.01 jgIml) in the presence of mAbs at the indicated concentrations. Results are given as 0
cpm, that is ['Hlthymidine incorporation in the presence of peptide minus incorporation by
T cells plus APC in the absence of peptide. (a) Background incorporation in the absence of
peptide was 803 ± 232 cpm and the specific response was 51,802 ± 3,724 cpm. (b) back-
ground incorporation was 1,998 ± 259 cpm and the specific response was 40,744 ± 1,823
cpm.
and the anti-class I antibody W6/32 having no effect. Presentation by the trans-
fectant was almost totally blocked by CA2, and Leu-3a inhibited the response by
^"70%. MHM 24 (anti-CD1la) had no effect, while MHM23 (anti-CD18) caused
a marginal reduction in the response. Thus, in the case of clone 2FI0, presen-
tation by the transfectant is inhibitable by blocking of the DR molecule or of
CD4 but is apparently not dependent on any interactions between LFA-1 on the
T cell and molecules expressed on the L cell.
Presentation of M. leprae and Recombinant 65-kD Antigen by the LDR2a Transfec-
tant. Since studies with L cells transfected with mouse class II genes have dif-
fered in their conclusions regarding the ability of the L cells to process native
antigens (5-7), we then tested the ability of the LDR2 a transfectant to present
nonpeptide antigens . As can be seen in Table I, the L cells were able to present
both the 65-kD recombinant M.leprae antigen and the mycobacterium to clone
2F10. Since previous experiments with M.leprae in this system showed that it
could be presented by paraformaldehyde-fixed B-LCL only if the cells were
pulsed with antigen before fixation, it can be concluded that the antigen is one
that requires processing and that these preparations are not contaminated by
immunogenic quantities of breakdown peptide (43). Interestingly, the L cell
transfectants were unable to act as accessory cells in the response of clone 2F10
to PHA. However, we observed heterogeneity with respect to mitogenic stimu-1450
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TABLE I
Presentation ofNative M .leprae Antigen, Recombinant 65-kD M.leprae Antigen, andPeptide to
T Cell Clone 2F10 by theLDR2a Transfectant
Results represent the means of triplicate cultures ±SE.
* M .leprae antigen was added to cultures at 20 jug/ml.
1 65-kD recombinant antigen was added to cultures at a final concentration of 10 fag/ml.
4Peptide p17 was added to cultures at a final concentration of 0.1 kg/ml.
e PHA was added to cultures at a final concentration of 4 ug/ml.
lation, some T cell clones responding to PHA in the presence of either trans-
fected or untransfected L cells (data not shown).
The DRa/DR2,B a Heterodimer Appears to be the Dominant Restriction Element
Used by DR2-restricted T Cells. The transfectant cell lines LDR2a and LDR2b
were then tested for their ability to present antigen to other DR2-restricted T
cells. T cell clone 2F9, which is derived from the same individual as 2F10, is also
DR2 restricted, and recognizes the 36-kD antigen of M.leprae (Elrerink, D., and
R. de Vries, unpublished observations). Clone 2136 derived from a
DR2Dw2,DR2Dw13 individual is also DR2 restricted, and is specific for
M.leprae. Both of the anti-M. leprae T cell clones respond to M .leprae antigen
when presented by the LDR2a transfectant but not the LDR2b transfectant
(Table 11). Thus, of the three T cell clones we tested from two different individ-
uals and specific for two different M.leprae antigens, all used the DR2# a chain
as their restriction element. Experiments in another system, the response to
Plasmodium falciparum circumsporozoite peptides by DR2-restricted T cell
clones, similarly showed that 4 of 4 clones used the DR2# a chain for presen-
tation and none the DR2# b chain (Altmann, D., D. Wilkinson, and F. Siniga-
glia, unpublished observations).
TABLE II
Use ofDR2,Ba Restriction Element by DR2-restricted TCell Clones
Results represent the means of triplicate cultures ±SE.
*M.teprae antigen was added to cultures at a final concentration of 1 lag/ml
IAutologous mononuclear leucocytes were used as APC.
APC Medium M .leprae* 65-kD antigenl Peptide§ PHAII
REIZ.LCL 1,431 + 261 15,082 ± 1,803 26,001 ± 818 88,664 ± 2,678 28,358 ± 1,460
LDR2a 4,597 ± 431 26,001 ± 818 49,809 ± 1,789 185,173 ± 12,540 2,831 ± 334
LDR2b 3,117 ± 1,563 1,891 ± 452 4,090 ± 296 2,493 ± 386 1,795 ± 218
LpSV2neo 213 ± 212 47 ± 16 99 ± 16 53 ± 4 813 ± 125
Clone Donor HLA DR APC Medium Antigen*
2F9 DR2Dw2,DR3 REIZ.LCL 1,290 ± 48 9,499 ± 698
LDR2a 4,951 ± 3,036 41,506 ± 1,954
LDR2b 1,937 ± 402 3,488 ± 257
SC2136 DR2Dw2,DR4,Dw13 SC MNLI 123 ± 38 45,977 ± 9,655
LDR2a 4,695 ± 469 14,523 ± 3,051
LDR2b 7,395 ± 296 6,928 ± 277WILKINSON ET AL.
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Discussion
Numerous studies on the transfection of mouse MHC class II genes into H2
class II-negative cells have generated a wealth of information on the structure
and function of these cell surface glycoproteins (reviewed in reference 4). In
contrast, relatively little work has been reported on the use of DNA-mediated
gene transfer to investigate the function of human, HLA class II genes (8, 9) .
Although much of the information gained from the murine system is relevant
to the study of human MHC class II structure and function, certain aspects of
the biology of HLA make an independent study of the function, serology, and
biochemistry of HLA class II products an important endeavor. Specifically, the
immunological role of these products in resistance to human diseases and the
basis of HLA/disease associations are questions of both fundamental and clini-
cal relevance. The very complexity of HLA makes the study of the encoded
products a challenging task. At least three products are expressed from the class
II region, HLA-DP, DQ, and DR, with two different DR products being
expressed in most haplotypes (10) . The linkage disequilibrium of some of these
genes, together with the scarcity of allele-specific mAbs, makes the contribution
of the individual gene products to HLA function less than unequivocal. The
DR2 haplotype exemplifies these problems: from biochemical and sequencing
studies, there are clearly two DR,Q genes expressed, but the relative importance
of these two products as restricting elements for class II-restricted, antigen-spe-
cific T cells is obscure. The transfection of defined HLA class II genes into cells
not normally expressing these products, is a means of dissecting this complexity
and offers the opportunity of studying unambiguously the functional, biochem-
ical, and serological characteristics of their encoded products.
An essential requirement for the work presented here was to produce trans-
fectants functionally capable of presenting antigen to human T cells. Studies by
Austin et al. (12) demonstrated that mouse L cells transfected with HLA-DP
genes could present antigen to an HLA-DP-restricted T cell clone, while another
report observed that L cells transfected with HLA-DRw52 were not capable of
presenting antigen to human T cell lines (11) . Such seemingly contradictory data
may hinge on the observation that there is a quantitative dependence of T cell
proliferative responses on the density of class II products on the APC surface
(5, 44), and that individual T cell clones differ in their requirement for accessory
molecule interactions (45) . We have used L cells as the recipient cells for trans-
fection of HLA class II genes, due to their class II-negative phenotype, and also
because the use of mouse cells offers the possiblity of using stepwise gene trans-
fection to explore the roles of other human gene products (e.g., LFA-1) in anti-
gen presentation. Given the importance of the level of class II expression on the
APC, we experimented with different cDNA expression vectors in order to gen-
erate transfectants stably expressing high levels of the transfected gene prod-
ucts. The mouse Moloney leukemia virus long terminal repeat (LTR)-based vec-
tor pJ4 is very efficient in L cells, giving significantly higher levels of cell surface
expression of class II genes than SV40-based vectors, in both transient and long-
term transfections (our unpublished observations). Transfection of L cells with
HLA class II a and ,Q genes cloned into pJ4 followed by microfluorimetric sort-
ing and single cell cloning has enabled us to produce transfectants expressing1452
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HLA class II products at a level approaching that seen on human B-LCL.
Transfectants expressing a single defined HLA class II product represent an
ideal means of defining unequivocally the specificities of anti-HLA class 11
mAbs, an exercise normally made difficult by the expression of multiple prod-
ucts from the class 11 region. When the two transfectants LDR2a and LDR2b
were screened with a panel of anti-HLA class 11 mAbs, the only mAb to distin-
guish between the transfectants was the mAb TDR31.1, and even in this case
the mAb bound to both, but with a higher affinity for the LDR2a transfectant.
This observation serves to illustrate the present limitations in the human system
ofusing mAbs as reagents for functional analysis of class II products. Although
many mAbs have been generated that are broadly reactive with HLA class 11
products, comparatively few allele-specific mAbs are available, presumably
because the polymorphic regions of human class 11 molecules are not the most
immunogenenic in the immunized mouse.
Although serologically similar, the migratory properties of the DR2# a and
DR20 b products when analyzed by 2D-PAGE are very different, the DR20 a
protein having a more acidic isoelectric point than the DR20 b protein. Com-
parison of the 2D gel patterns obtained for the DR2Dw2 B-LCL, PGF, and the
LDR2a and LDR2b transfectants clearly demonstrates that: (a) The individual a
chains in the transfectants have electrophoretic mobilities indistinguishable from
the /3 chains in the human B cell, suggesting that there are no gross differences
in posttranslational modification of the human proteins when expressed in
human and mouse cells, in agreement with previous observations (46); and (b)
the more acidic set of ,Q spots in the DR2Dw2 B-LCL immunoprecipitate are
encoded by the DR2f a sequence, and the more basic set of spots by the DR2#
b sequence. This result is a formal proof of the predictions made from studies
correlating cDNA sequences with electrophoretic mobilities for the DR# genes
of the DR2 haplotype (18, 19).
Leprosy is a disease where infection of different individuals with the same
bacillus leads to a wide range of clinical phenotypes, from lepromatous leprosy,
where there is a state of immunological unresponsiveness, to tuberculoid lep-
rosy, where there is a state of immunological hyperresponsiveness (47). The
observation that the type of pathology developed is at least partly dependent
upon the HLA type of the individual (20) makes leprosy an exciting model for
looking at human Ir gene effects. The DR2 allele is overrepresented in both
tuberculoid (15) and lepromatous patients, the association in the latter group
possibly reflecting linkage disequilibrium with DQwl(48). Given these associa-
tions and the clear evidence of pathology caused by a problem of immune reg-
ulation, there has been enormous interest in mapping the epitopes on M.leprae
seen by T cells from leprosy patients and the association of M.leprae antigens
with HLA class 11 molecules (39, 40) with a view to advanced vaccine design
(21). Substantial progress has been made in the analysis of epitopes on myco-
bacterium recognized by DR2-restricted T cell clones (49), but precise mapping
of the interaction between peptide, HLA class 11 molecule, and T cell receptor
has been hampered by the inability to identify unambiguously the restriction
element used by the T cell.
Studies using homozygous B-LCL as APC for clone 21710, a T cell specific forWILKINSON ET AL.
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a peptide (Anderson, D., et al. manuscript in preparation) from the 65-kD anti-
gen of M.leprae in association with DR2Dw2 showed that Dw2 or Dw12 B cells
served equallywell for presentation. Thus, it was unclear whether the restriction
element for presentation of the peptide lay on the DR20 a or DR2;8 b chain.
Our attempt to answer this question using transfectants independently express-
ing each of the expressed DR2 products definitively showed that the LDR2a
transfectant presented peptide efficiently to clone 2F10, while the LDR2b trans-
fectant was unable to do so. Thus, in spite of the ability of Dw2 and Dw12 B
cells to present antigen to clone 2F10, it is the more variable DR2f a chain that
acts as the restriction element. Comparison of ,81 domain sequences of DR,B
alleles shows that there are essentially three areas of hypervariability, these being
in the regions of amino acid residues 4-14, 25-33, and 67-74. The Dw2,8 a and
Dw12,8 a chains have similar sequences in the first and third hypervariable
regions, but differ markedly in the second. Thus, it is likely that the ability to
bind and present peptide to clone 2F10 by both Dw2 and Dw12 B-LCL is
dependant upon residues in the first and/or third hypervariable regions. In this
connection it is noteworthy that the DR2 B-LCL AZH, which has undergone a
recombination event such that its ,8 a chain is identical to the Dw2/Dw12 /3 b
chain in the third hypervariable region, is unable to present peptide to this clone
(de Vries, R., D. Elferink & N. Reinsmoen, unpublished observation).
Of two other anti-M. leprae clones known to proliferate in response to anti-
gen presented by DR2 cell lines, both use the DR2,8 a chain as restriction ele-
ment. Similarly, our more recent observations on DR2-restricted T cell clones
against a P. falciparum peptide, together with the studies ofJacobson et al. (50)
who correlated the more electrophoretically variable DR,8 chain in DR2 haplo-
types with the restriction element used by DR2-restricted, measles-specific CTL,
implicate the DR2,# a chain as the dominant DR2;8 restriction element. The role
of the DR2# b chain in DR2 restriction may thus be analogous to the DRw52
and DRw53 supertypic specificities, which probably as a consequence of their
low cell surface expression compared with the more variable DR,B chain prod-
ucts (51), rarely function as T cell-restricting elements. In a similar vein, our
preliminary studies on alloreactivity using the LDR2a and LDR2b transfectants
suggest that the DRa/DR20 a heterodimer is the immunodominant DR product
in the mixed lymphocyte response (data not shown).
The ability of the LDR2a transfectant to present peptide to clone 2F10
unequivocally demonstrates that expression of an HLA-DR a/# heterodimer on
a mouse L cell is necessary and sufficient for recognition by the T cell. Fur-
thermore, the response elicited was of a similar magnitude whether using the B-
LCL or transfectant. As previously reported for presentation of antigen by I-A-
transfected L cells to mouse T cell clones, presentation by LDR2a to clone 2F10
led to specific cytolysis of the L cell (52), although we have been unable to
detect killing in short-term 5'Cr-release assays (data not shown) .
Our antibody blocking studies showed that presentation by the transfectant
could be blocked by the anti-class II framework mAb CA2 or by an anti-CD4
mAb but not irrelevant mAbs (anti-DQ, anti-HLA class 1). The similar pattern
of CD4 blocking seen on transfectants and B cells corroborates the findings of
others using HLA-DR transfectants that the HLA class 11 molecule is the ligand1454
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for CD4 and that this interaction plays an important part in the interaction
between CD4' lymphocytes and 1a'APCs (53). While presentation by the B-LCL
was significantly inhibited by mAbs against CDIIa (LFA-Ia) or CD18 (LFA-1#
), these mAbs had no effect on presentation by the transfectants. This is in line
with the notion that the function of LFA-1 in T cell/APC interactions represents
a nonobligatory means of enhancing intercellular avidity (54), and that the
ligand for LFA-1, probably I-CAM-1, is not expressed on the surface of the L
cell. These observations confirm those made in studies of presentation by mo
transfectants to mouse T cell clones (5, 54) . While it is hard to reconcile this
view with the findings of Cowan et al. (55) who reported inhibition of human
CTL lysis of mouse HLA-A3 transfectants with antibodies to LFA-1, it could be
that even weak interactions resulting from binding of human LFA-1 to xeno-
geneic ligands on the L cell are important in the adhesion steps leading to
cytolysis.
Experiments using mouse T lymphocytes and mouse la transfectants have not
produced a clear consensus as to whether L cells can serve all the normal anti-
gen processing requirements of a conventional APC. While studies using some
whole protein antigens, for example keyhole limpet hemocyanin, have suggested
that L cells can indeed process antigen normally (5), other antigens, for example
hen eggwhite lysozyme, were only recognized when presented as synthetic pep-
tides (6). We found the LDR2a transfectants were efficient at presenting syn-
thetic peptide, recombinant 65-kD M. leprae antigen or whole M. leprae. Anti-
gens that can be presented in this way by cells that are not of any specialized
antigen presenting lineage might be expected to be in the majority, since the
cathepsins which have been implicated in lysosomal degradation of protein anti-
gens by conventional APCs (56) are also found in many other cell types, includ-
ing L cells (57).
Despite the efficient presentation of an
have so far found it difficult to demonstrate ant
lated T cells or stimulation o£ a primary MLR by the transfectants. This is some-
cent of earlier models looking at L cell present
cells where primary MLRs, when detectable, have been low, and most work has
been done with T cell hybridomas (5) . Furthermore we found that some M.leprae
T cell clones which from panel studies on HLA-typed APC were expected to be
restricted by one of the two DR products from the DR2Dw2 haplotype, failed
to proliferate to antigen when presented by either LDR2a or LDR2b. Given that
these transfectants express high levels of HLA class II products and are capable
of presenting native antigens to human T cells, this observation may be a reflec-
tion of a heterogeneity amongst human T cells in terms of TCR affinity and
dependence upon accessory molecule function. We are currently investigating
this notion by introducing ICAM-1 (58), a known ligand of LFA-1, into the
transfected cell lines.
The establishment of a system whereby transfected human DR molecules can
be studied in a clinically relevant, functional model represents an exciting devel-
opment in analysis of the HLA complex. Having developed a model whereby
the role of HLA class II molecules presenting antigen to human T cell clones
can be studied in a defined way, we are now investigating the nature of the
ablished T cell clones, we
gen presentation to freshly iso-WILKINSON ET AL.
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interaction between Ia, peptide and the TCR using site-directed mutagenesis of
the tranfected HLA class 11 genes and substituted antigenic peptides.
Summary
We have used DNA-mediated gene transfer to express HLA class II molecules
in mouse L cells for serological, biochemical, and functional analysis. cDNA
clones encoding the DR2# a and DR2# b products of the DR2Dw2 haplotype
were subcloned into a mouse Moloney leukemia virus-based expression vector
(pJ4) and transfected separately into mouse L cells together with a HI.A-
DRa/pJ4 construct. These transfectants have allowed differential analysis of the
two DR2Q products in a manner normally prohibited by the concomitant expres-
sion seen in B cells. Two-dimensional SDS-PAGE analysis of the transfectants
defines the more acidic 0 chain as the product of the DR2# a sequence, and the
more basic chain as the product of the DR2,6 b sequence. The LDR2a transfec-
tants present antigen efficiently to M.leprae-specific T cell clones and are capa-
ble of presenting synthetic peptide, 65-kD recombinant mycobacterial antigen
and M.leprae. Of the DR2Dw2-restricted T cell clones we have tested, all use the
DR2f a chain as their restriction element. Inhibition studies with mAbs dem-
onstrate the dependence of presentation by the transfectant on class II and
CD4, while mAbs against LFA-1, which substantially inhibit presentation by B-
lymphoblastoid cell lines, do not inhibit transfectant presentation.
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tides. Dr. Li Shunguang kindly allowed us to use his T cell clone 2D6. We would also
like to thank D. Elferink for technical assistance and D. Carpenter for FACS analysis.
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